01st week of 2019 patent applcation highlights part 26 |
Patent application number | Title | Published |
20190002515 | NOVEL GENERATION OF ANTIGEN-SPECIFIC TCRS - The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described. | 2019-01-03 |
20190002516 | Drug Design Method, Obtained Drug and Application Thereof - Provided is a drug system design method, comprising selecting a target moiety specifically binding to a target of interest, and connecting the target moiety to a biologically active moiety and/or connecting the target moiety to a biologically inert moiety. Also provided are a test kit, a drug kit or a pharmaceutical composition including a biologically inert drug comprising the target moiety and the biologically inert moiety and a biologically active drug comprising the target moiety and the biologically active moiety, wherein the biological inert drug and the biologically active drug target a same target. Also provided is a method for using the drugs or the pharmaceutical composition to treat diseases such as those related to ED-B. | 2019-01-03 |
20190002517 | NEUROPEPTIDE Y-DERIVED PEPTIDES - The present invention discloses peptide fragments derived from neuropeptide Y (NPY), which are capable of selective binding to the neural cell adhesion molecule (NCAM) and inducing neuroplastic and neuroprotective effects, and the use of said peptide fragments as neuritogenic agents for treatment of pathological conditions in which neuroprotection and neuroplastic changes are desired, such as brain and retina disorders. | 2019-01-03 |
20190002518 | METHODS OF PURIFICATION AND/OR VIRAL INACTIVATION - Methods of purification and/or viral deactivation of a protein (e.g. glycoprotein) comprising a step of treating the protein (e.g. glycoprotein) with a combination of caprylic acid and ethanol. | 2019-01-03 |
20190002519 | PRO-DRUG PEPTIDE WITH IMPROVED PHARMACEUTICAL PROPERTIES - The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n≥2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder. | 2019-01-03 |
20190002520 | TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST - The present invention relates to a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof. | 2019-01-03 |
20190002521 | THERAPEUTIC AGENTS - An immunoresponsive cell, such as a T-cell expressing
| 2019-01-03 |
20190002522 | COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS FOR DIRECT RECOGNITION OF TUMOR ANTIGEN - Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a NY-ESO-1 antigen. Included are recombinant T cell receptors (TCRs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including CD4 | 2019-01-03 |
20190002523 | T CELL RECEPTORS SPECIFIC FOR THE NY-ESO-1 TUMOR ANTIGEN-HLA-A*02 COMPLEX - The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease. | 2019-01-03 |
20190002524 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-01-03 |
20190002525 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-01-03 |
20190002526 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-01-03 |
20190002527 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRPV4 - TRPV4 activation increases vascular permeability and can be triggered by both chemical and mechanical cues. This activation of TRPV4 can contribute to a number of pathological conditions, e.g., edema, inflammation, hypertension, and/or hyperalgesia. Described herein are methods and compositions relating to inhibition of mechanically-induced TRPV4 activation, e.g., for the treatment of pulmonary edema, edema, inflammation, hypertension, and/or hyperalgesia. | 2019-01-03 |
20190002528 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DRY EYES - The present invention relates to a pharmaceutical composition for preventing or treating dry eye, the pharmaceutical composition including, as an active component, a novel peptide is disclosed, wherein it is confirmed that the peptide has effects on improving tear production and corneal surface smoothness for dry eyes induced by desiccation stress and suppressing detachment of corneal epithelial cells, reduction in conjunctival goblet cells, and generation of inflammatory factors, thereby applying a composition including the peptide as an active component to the pharmaceutical composition for preventing or treating dry eye. | 2019-01-03 |
20190002529 | Assembly of Intermediate Filament Proteins in to Filamentous Materials - Intermediate filament (IF) recombinant protein, such as from hagfish, can be purified under denaturing conditions either as a single protein (alpha or gamma alone) or assembled in a 1:1 molar ratio (alpha plus gamma). Step-down renaturation (protein refolding) or rapid dilution refolding is followed by formation of IF threads. | 2019-01-03 |
20190002530 | GELATIN PARTICLES, METHOD FOR PRODUCING GELATIN PARTICLES, GELATIN PARTICLE-CONTAINING CELL, AND METHOD FOR PRODUCING GELATIN PARTICLE-CONTAINING CELL - Disclosed herein are gelatin particles including gelatin, wherein when a major-axis length of dried gelatin particles is defined as a and a major-axis length of gelatin particles after swelling treatment obtained by immersing the dried gelatin particles in water at 40° C. under an atmospheric pressure for 60 minutes is defined as b, swelling degree represented by b/a is 1.0 or more but 10.0 or less, and wherein the gelatin particles after swelling treatment have a particle diameter of 1.0 nm or more but 5.0 μm or less. The gelatin particles are easily taken up by cells themselves. | 2019-01-03 |
20190002531 | MIMETIC PEPTIDES DERIVED FROM COLLAGEN TYPE IV AND THEIR USE FOR TREATING ANGIOGENESIS- AND LYMPHANGIOGENESIS- DEPENDENT DISEASES - Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties. | 2019-01-03 |
20190002532 | METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES - In some embodiments, the invention relates to methods for creating a monoclonal antibody that specifically binds to antigen. The method may start from a polyclonal population of antibodies such as a non-specific polyclonal population or a polyclonal population of antibodies that specifically bind to the antigen. The method includes obtaining nucleic acid molecules encoding heavy and light immunoglobulin chains (or variable regions thereof) of multiple immunoglobulins from an animal; obtaining mass spectra information of peptide fragments of a population of polyclonal immunoglobulins that specifically bind to an antigen of choice; comparing and/or correlating the mass spectra information of the peptide fragments of the polyclonal immunoglobulins with predicted mass spectra information of predicted amino acid sequences encoded by the nucleic acid molecules, and then assembling the heavy and light chains to create an antibody (or variable region thereof) that specifically binds to the antigen. | 2019-01-03 |
20190002533 | POLYOMAVIRUS NEUTRALIZING ANTIBODIES - The present disclosure is directed to anti-VP1 antibodies, antibody fragments, and their uses for the reducing the likelihood or treatment of polyoma virus infection. | 2019-01-03 |
20190002534 | HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - The invention provides human antibodies against rabies and methods of using the same. | 2019-01-03 |
20190002535 | ANTIBODY CAPABLE OF BINDING TO NOROVIRUS, COMPOSITE, DETECTION DEVICE AND METHOD USING THE SAME - The present invention provides a novel antibody capable of binding to a norovirus. The present invention is an antibody that consists of an amino acid sequence, wherein said amino acid sequence consists of, in an N- to C-direction, the following structural domains: | 2019-01-03 |
20190002536 | NOVEL HA BINDING AGENTS - This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use. | 2019-01-03 |
20190002537 | METHOD FOR ENRICHING A PREPARATION OF IMMUNOGLOBULINS WITH ANTI RSV IMMUNOGLOBULINS AND PREPARATION ENRICHED IN THIS WAY - Disclosed is a method for preparing an immunoglobulin (Ig) concentrate useful for treating RSV infection, including a step consisting in subjecting an Ig composition derived from blood plasma to affinity chromatography utilizing an RSV-specific ligand. In a particular embodiment, the RSV-specific ligand is an RSV F protein, preferentially in prefusion conformation, or a variant or an antigenic fragment thereof. | 2019-01-03 |
20190002538 | ANTIBODIES THAT POTENTLY NEUTRALIZE RSV AND USES THEREOF - The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection. | 2019-01-03 |
20190002539 | BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV-1 AND USE THEREOF - Broadly neutralizing antibodies against HIV-1 which specifically bind to gp120 of HIV-1, a method of preparing such antibodies and the use thereof are provided. | 2019-01-03 |
20190002540 | METHODS OF TREATING S. AUREUS-ASSOCIATED DISEASES - The present invention provides for methods of preventing and/or treating | 2019-01-03 |
20190002541 | MODULATING THE ALTERNATIVE COMPLEMENT PATHWAY - Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins. | 2019-01-03 |
20190002542 | TRANSGLYCOSYLATION OF ENDO-S AND ENDO-S MUTANTS FOR ANTIBODY GLYCOSYLATION REMODELING - The present invention provides for a one-pot enzymatic approach which does not require removal of the enzyme and purification of the intermediate after deglycosylation step, and the Endo-S treatment is able to do both deglycosylation and transglycosylation. The one-pot strategy of the present invention enables chemoenzymatic synthesis of an azido-tagged N-glycoform of monocloncal antibodies which could be further modified through orthogonal chemical ligation for various applications. | 2019-01-03 |
20190002543 | Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody - Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result. | 2019-01-03 |
20190002544 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS - Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains. | 2019-01-03 |
20190002545 | Anti-Malarial Compositions - This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of | 2019-01-03 |
20190002546 | METHODS AND COMPOSITIONS FOR BINDING VEGF - The present invention relates to fusion polypeptide compositions comprising immunoglobulin-type-2 binding domains of Vascular Endothelial Growth Factor Receptor, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions. | 2019-01-03 |
20190002547 | METHODS FOR TREATMENT OF MOTOR NEURON DISEASES - The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided. | 2019-01-03 |
20190002548 | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE - The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue. Anti-myostatin antibodies of the present invention may be for use in increasing strength of muscle tissue. | 2019-01-03 |
20190002549 | ANTI-GM-CSF ANTIBODIES AND USES THEREOF - Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders. | 2019-01-03 |
20190002550 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS - The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis. | 2019-01-03 |
20190002551 | METHODS OF MODIFYING ANTIBODIES, AND MODIFIED ANTIBODIES WITH IMPROVED FUNCTIONAL PROPERTIES - The invention provides methods of using sequence based analysis and rational strategies to modify and improve the structural and biophysical properties of immunobinders, and in particular of single chain antibodies (scFvs), including such properties as stability, solubility, and/or antigen binding affinity. The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions at amino acid positions identified by analysis of a database of selected, stable scFv sequences, wherein preferred amino acid residues for substitution have been identified. The invention also provides immunobinders prepared according to the engineering methods of the invention. The invention also provides preferred scFv framework scaffolds, into which CDR sequences can be inserted, as well as scFv antibodies made using these preferred framework scaffolds. | 2019-01-03 |
20190002552 | ANTIBODY FORMULATIONS - Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations. | 2019-01-03 |
20190002553 | TREATMENT OF FIBROSIS - Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed. | 2019-01-03 |
20190002554 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies - This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. | 2019-01-03 |
20190002555 | ANTIGEN-BINDING PROTEINS TO MARINOBUFAGENIN - The present invention provides monoclonal antigen-binding proteins that bind to the cardiac glycoside marinobufagenin (MBG), and methods of use. In various embodiments of the invention, the antigen-binding proteins are fully human antigen-binding proteins that bind to MBG. In some embodiments, the antigen-binding proteins of the invention are useful for inhibiting or neutralizing MBG activity, thus providing a means of treating or preventing a MBG-associated disease or disorder selected from the group consisting of hypertension, myocardial fibrosis, uremic cardiomyopathy, heart failure, myocardial infarction, renal failure, renal fibrosis and pre-eclampsia. | 2019-01-03 |
20190002556 | NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME - The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention. | 2019-01-03 |
20190002557 | MITIGATING TISSUE DAMAGE AND FIBROSIS VIA LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN (LTBP4) - The disclosure relates to compositions and methods of mitigating tissue damage and fibrosis in a patient by modulating latent transforming growth factor beta binding protein (LTBP4)-induced proteolysis of a TGFβ superfamily protein. | 2019-01-03 |
20190002558 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND ISOLATION OF CELL-MEMBRANE PROTEIN SPECIFIC BINDING MOIETIES - Disclosed are methods of identifying binding moieties that recognize antigens displayed on cells, such as membrane proteins or recombinant proteins that display eptiopes on the surface of cells. Binding moieties capable of binding membrane proteins can be difficult to obtain because these proteins can depend on their native environments for structural integrity. In some methods scFv phage display libraries are panned against whole cells expressing a membrane protein in an emulsion. Certain methods further permit discrimination of binding moieties according to their affinity or avidity for a target. This approach allows rapid identification of cell surface epitope specific antibodies for research, diagnostics, and immunotherapeutics. | 2019-01-03 |
20190002559 | ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES - The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer. | 2019-01-03 |
20190002560 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | 2019-01-03 |
20190002561 | CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY - The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia. | 2019-01-03 |
20190002562 | Caninized Antibodies - The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs. | 2019-01-03 |
20190002563 | Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof - The present invention is directed to B7-H3×CD3 bispecific monovalent diabodies, and particularly, to B7-H3×CD3 bispecific monovalent Fc diabodies, that are capable of simultaneous binding to B7-H3 and CD3. The invention is also directed to pharmaceutical compositions that contain such bispecific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions. | 2019-01-03 |
20190002564 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 2019-01-03 |
20190002565 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 2019-01-03 |
20190002566 | MODIFIED J-CHAIN - The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses. | 2019-01-03 |
20190002567 | NEW USE OF AN ANTI-CD303 TRANSMEMBRANE PROTEIN ANTIBODY - Disclosed is an anti-CD303 protein antibody for use in the prophylaxis or therapy of a tumor, involving plasmacytoid dendritic cell activation in the environment of the tumor, said plasmacytoid dendritic cells not being the cause of the tumor. | 2019-01-03 |
20190002568 | BISPECIFIC FC MOLECULES - Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules. | 2019-01-03 |
20190002569 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway - The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway. | 2019-01-03 |
20190002570 | METHOD FOR SELECTION AND PRODUCTION OF TAILOR-MADE HIGHLY SELECTIVE AND MULTI-SPECIFIC TARGETING ENTITIES CONTAINING AT LEAST TWO DIFFERENT BINDING ENTITIES AND USES THEREOF - Herein is reported a method for producing a bispecific antibody comprising the step of incubating
| 2019-01-03 |
20190002571 | INHIBITION OF CCL5 LIGAND BINDING TO CCR5 RECEPTOR AND ALTERATION OF CCR5/CCL5 AXIS SIGNALING IN INFLAMMATION, CANCER, AUTOIMMUNE, AND OTHER CONDITIONS - Methods for the therapeutic use of competitive inhibitors of the CCR5/CCL5 axis that express antagonist activity for RANTES (CCL5) for immunomodulatory treatment of subjects in need thereof. The competitive inhibitors may not have CCL5 agonist activity and can be used to inhibit, interrupt, block, mitigate, slow the progress of, and/or treat inflammation and/or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with transplantation, including graft versus host disease, autoimmune disorders, infectious agents, chronic inflammation, and cancer, etc. | 2019-01-03 |
20190002572 | PREVENTIVE AND/OR THERAPEUTIC METHOD FOR SYSTEMIC LUPUS ERYTHEMATOSUS COMPRISING ANTI-IL-6 RECEPTOR ANTIBODY ADMINISTRATION - A preventive and/or therapeutic agent for systemic lupus erythematosus comprising an anti-interleukin-6 (IL-6) receptor antibody as an active ingredient. | 2019-01-03 |
20190002573 | CD123 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY - The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia. | 2019-01-03 |
20190002574 | Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2019-01-03 |
20190002575 | METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS - A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject. | 2019-01-03 |
20190002576 | ANTIBODY THERAPEUTICS THAT BIND CD123 - There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease. | 2019-01-03 |
20190002577 | Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies - The present invention relates to methods of treating Type 2 diabetes (T2D), comprising administering to a patient an effective amount of an isolated antagonistic antigen binding protein that specifically binds to the human glucagon receptor, either as monotherapy, or in combination with one or more antidiabetic medications. | 2019-01-03 |
20190002578 | Targeted Protein Degradation - The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled. | 2019-01-03 |
20190002579 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY - Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids. | 2019-01-03 |
20190002580 | HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 - The present invention relates to immunology, biotechnology and medicine, notably to the field of antitumor pharmaceuticals based on monoclonal antibodies, and can be used in medicine for the treatment of oncological diseases. | 2019-01-03 |
20190002581 | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES - Provided herein are antibodies that selectively bind to EpCAM and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods. | 2019-01-03 |
20190002582 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING OVARIAN CANCER - The present invention relates to methods for the in vitro diagnosis of ovarian cancer, and to compositions and methods for the prevention or the treatment of ovarian cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin. | 2019-01-03 |
20190002583 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS - A combination which comprises an effective amount of Her2/Neu antagonist and an effective amount of immunotherapeutic that is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, NK cell, or a combination thereof is disclosed. | 2019-01-03 |
20190002584 | A MONOCLONAL ANTIBODY INHIBITOR OF FACTOR XIIA - Disclosed herein are anti-Factor Xlla antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases. | 2019-01-03 |
20190002585 | CANCER TREATMENT METHODS AND COMPOSITIONS - Provided herein are compositions, systems, kits, and methods for treating cancer by administering to a subject a first agent selected from: a PDE12 inhibiting agent, a AKAP7 inhibiting agent, an ADAR1 inhibiting agent, and/or a RNase L enhancer, and a second agent that comprises a DNA methylation inhibiting agent (e.g., a DNA methyltransferase demethylase inhibitor). | 2019-01-03 |
20190002586 | METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS - Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided. | 2019-01-03 |
20190002587 | MONOCLONAL ANTI-TK1 ANTIBODIES - The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments. | 2019-01-03 |
20190002588 | ANTI-MYL9 ANTIBODY - The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced. | 2019-01-03 |
20190002589 | METHOD OF MANUFACTURING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES - The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines. | 2019-01-03 |
20190002590 | CIRCULAR TANDEM REPEAT PROTEINS - Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses. | 2019-01-03 |
20190002591 | ACYLATION OF BIOPOLYMER COMPRISING ANHYDROGLUCOSE UNITS - A process for the preparation of particulate acylated biopolymer comprising anhydroglucose units that comprises several steps. First, dispersing an amount of particulate non-surface modified biopolymer comprising anhydroglucose units in an amount of a liquid alkenyl carboxylatein order to form a first dispersion. Then, adding a catalytic composition to the first dispersion such a to form a second dispersion, heating the second dispersion to a temperature above ambient temperature, and cooling the second dispersion to ambient temperature. Thereafter, the obtained particulate acylated biopolymer is isolated. The amount of a liquid alkenyl carboxylate corresponds to a molar excess of alkenyl carboxylate, the molar excess being defined with respect to the moles of anhydroglucose units comprised in the amount of the particulate non-surface modified biopolymer. The catalytic composition comprises an amount of one, or two or more, non-nucleophilic bases. | 2019-01-03 |
20190002592 | Milling Process - A process for treating crop kernels is comprised of the steps of a) soaking kernels in water to produce soaked kernels; b) grinding the soaked kernels; c) treating the soaked kernels in the presence of an effective amount of GH62 polypeptide having arabinofuranosidase activity or a GH43 polypeptide having arabinofuranosidase activity, wherein step c) is performed before, during or after step b). | 2019-01-03 |
20190002593 | PROCESS FOR THE PRODUCTION OF THERMALLY MODIFIED STARCH - Process for the production of thermally modified starch comprising the steps of mixing starch in powder form having a specific moisture content with an alkaline water solution to obtain a wet powder; feeding a continuous flow of said wet powder into a continuous dryer together with a continuous flow of hot air; discharging a continuous flow of dried powder from said continuous drier; supplying said continuous flow of said dried powder into a turbo-reactor, in which the inner wall of said turbo-reactor is maintained at a specific temperature; converting said dried powder into a thermally inhibited starch; and discharging said thermally inhibited starch from said turbo-reactor; it is also disclosed a thermally inhibited starch obtained from the aforementioned process with enhanced physical chemical properties. | 2019-01-03 |
20190002594 | Chitosan-Derived Compositions - The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders. | 2019-01-03 |
20190002595 | FUCOIDAN PREPARATION, ZINC-BOUND FUCOIDAN AND USE THEREOF - Provided is a technique for enhancing the absorption of fucoidan into the body and elevate various effects of fucoidan by using a fucoidan preparation that is characterized by containing fucoidan and zinc and the ratio of zinc to fucoidan being 0.005% or greater. | 2019-01-03 |
20190002596 | SULFATED HEPARIN OLIGOSACCHARIDE AND PREPARATION METHOD AND APPLICATION THEREOF - Provided are a sulfated heparin oligosaccharide as well as a preparation method and an application thereof. The sulfated heparin oligosaccharide molecule contains an unsaturated double bond resulting from enzymolysis by heparinase at the non-reducing end thereof, an uronic acid derivative and a glycosylamine derivative; and has a structure represented by formula I, wherein R | 2019-01-03 |
20190002597 | PROCESS FOR EPOXIDATION OF UNSATURATED POLYMER - A process for epoxidation of an unsaturated polymer involves mixing an unsaturated polymer and a peroxy acid in an absence of solvent to produce an epoxidized polymer. The process may require no solvent, require no catalyst, require no or little applied external heat input, require no applied cooling, require less epoxidation agent, be faster and/or result in more efficient conversion of the unsaturated polymer. | 2019-01-03 |
20190002598 | AZASILANE-BASED MODIFIER, AND METHOD FOR PREPARING MODIFIED AND CONJUGATED DIENE-BASED POLYMER USING THE SAME - The present invention provides an azasilane-based modifier of Formula 1, which may easily introduce a functional group having affinity with a filler into a conjugated diene-based polymer chain, a modified and conjugated diene-based polymer including the functional group derived from the azasilane-based modifier, a method for preparing the modified and conjugated diene-based polymer, a rubber composition including the modified and conjugated diene-based polymer, and a molded article and a tire manufactured from the rubber composition. | 2019-01-03 |
20190002599 | TIRE COMPRISING A RUBBER COMPOSITION INCLUDING A SUBSTITUTED DIENE ELASTOMER - A tire comprising a rubber composition comprising a substituted diene elastomer is provided. The substituted diene elastomer comprises units bearing an A-B radical, in which:
| 2019-01-03 |
20190002600 | METHOD OF SUSPENSION POLYMERIZATION OF DROPLETS DISTRIBUTED IN AN AQUEOUS MEDIUM - Provided is a method of suspension polymerization comprising
| 2019-01-03 |
20190002601 | PROCESS FOR MAKING A SOLID CATALYST COMPONENT FOR ETHYLENE POLYMERIZATION AND CO-POLYMERIZATION - The present invention relates to a process for preparing a solid catalyst component suitable for producing polyethylene and its copolymers, said process comprising the steps of: (a) contacting a dehydrated support having hydroxyl groups with a magnesium compound having the general formula MgR | 2019-01-03 |
20190002602 | CAST FILMS, AND ARTICLES MADE THEREFROM - Disclosed herein is a cast film comprising a polyethylene composition comprising the reaction product of ethylene and optionally one or more alpha-olefin comonomers, wherein said polyethylene composition is characterized by the following properties: a melt index, I2, measured according to ASTM D1238 (2.16 kg, 190° C.), of from 1 to 20 g/10 min; a density (measured according to ASTM D792) of from 0.935 to 0.970 g/cm3; a melt flow ratio, I | 2019-01-03 |
20190002603 | Process for Preparing a Polyethylene in at Least One Continuously Stirred Tank Reactor - Processes for preparing a polyethylene in at least one continuously stirred tank reactor are described herein. The process may comprise the step of: polymerizing ethylene in the presence of at least one supported metallocene catalyst, a diluent, optionally one or more co-monomers, and optionally hydrogen, thereby obtaining the polyethylene, wherein the supported metallocene catalyst comprises a solid support, a co-catalyst and at least one metallocene, wherein the solid support has a surface area within the range of from 100 to 500 m2/g, and has a D50 value within the range of from 4 μm to 18 μm, with D50 being defined as the particle size for which fifty percent by weight of the particles has a size lower than the D50; and D50 being measured by laser diffraction analysis on a Malvern type analyzer. Polyethylene obtained by the disclosed process and articles comprising the polyethylene are also described. | 2019-01-03 |
20190002604 | HETERORING-CONTAINING SILOXANE POLYMER, COMPOSITION CONTAINING SAID POLYMER, AND ELECTRONIC ELEMENT - An object of the present invention is to provide a novel hetero ring-containing siloxane polymer, a composition and an electronic material composition containing the polymer, and an electronic element, which do not cause a decrease in luminous efficiency and driving stability of an electronic element, by adding the polymer to an electronic material composition or ink to be used for coating film formation. It has been found that the electronic element produced from the novel hetero ring-containing siloxane polymer, the composition and the electronic material composition containing the polymer exhibit improved luminous efficiency and driving stability, thereby completing the present invention. | 2019-01-03 |
20190002605 | LOW TEMPERATURE CROSS LINKABLE POLYCHLOROPRENE COMPOSITIONS - Essentially ethylene thiourea free cross linkable composition comprising a chloroprene rubber having defined contents of cations from the second or third main group and resinate anions are provided, which possess improved curing characteristics for increased productivity and lower vulcanization temperatures for energy-saving manufacturing methods and vulcanizates obtained by using said chloroprene rubber. | 2019-01-03 |
20190002606 | Ethylene-Based Polymers with Low Hexane Extractables and Low Densities - Ethylene-based polymers comprising the following properties: (A) a density less than 0.9190 g/cc; (B) a hexane extractable level that meets the following equation: hexane extractable level ≤A+B [log(12)], where A=2.65 wt %. and B—0.25 wt %[log (dg/min)]; based on total weight of the ethylene-based polymer; (C) a G′ (at G″=500 Pa, 1 70° C.) that meets the following equation: G′≥C+D [log(12)], where C=150 Pa, and D=−60 Pa/[log(dg/min)]; and (D) a melt index (12) from 0.7 to 20 dg/min; are made in high pressure tubular process that comprises at least three reaction zones with the peak polymerization temperature of the first reaction zone ≥320° C. and the peak polymerization temperature of the last reaction zone ≤290° C. | 2019-01-03 |
20190002607 | Polymerization Initiating System And Method To Produce Highly Reactive Olefin Functional Polymers - A method for producing highly reactive olefin polymers wherein at least 50 mol. % of the polymer chains have terminal double bonds, from an impurity-containing isobutylene or a mixed C | 2019-01-03 |
20190002608 | THERMOPLASTIC ELASTOMERS VIA REVERSIBLE ADDITION-FRAGMENTATION CHAIN TRANSFER POLYMERIZATION OF TRIGLYCERIDES - The present invention relates to a thermoplastic block copolymer comprising at least one PA block and at least one PB block. The PA block represents a polymer block comprising one or more units of monomer A, and the PB block represents a polymer block comprising one or more units of monomer B. Monomer A is a vinyl, acrylic, diolefin, nitrile, dinitrile, acrylonitrile monomer, a monomer with reactive functionality, or a crosslinking monomer. Monomer B is a radically polymerizable triglyceride or mixtures thereof, typically in the form of a plant or animal oil. The present invention also relates to a method of preparing a thermoplastic block copolymer or novel thermoplastic statistical copolymers by polymerizing a radically polymerizable monomer with a radically polymerizable triglyceride or mixtures thereof via reversible addition-fragmentation chain-transfer polymerization (RAFT), in the presence of an free radical initiator and a chain transfer agent. | 2019-01-03 |
20190002609 | LIPID ANALOGS AND LIPOSOMES COMPRISING SAME - A polymeric compound is disclosed herein, having the general formula I: | 2019-01-03 |
20190002610 | PROCESS FOR PREPARING POLYMER COMPOSITIONS - The present invention relates to an olefin polymerization process, wherein propylene and a C4 to C10 α-olefin monomer, preferably 1-butene- and optionally ethylene are reacted in the presence of a Ziegler-Natta catalyst so as to obtain a polypropylene, wherein the polypropylene comprises C4 to C10 α-olefin, preferably 1-butene-derived comonomer units in an amount of from 0,5 to 15 wt % and ethylene-derived comonomer units in an amount of 0 to 3 wt %, and wherein the Ziegler-Natta catalyst comprises i) an external donor of the formula (I): (R | 2019-01-03 |
20190002611 | Ultra-High Molecular Weight Ethylene-Based Copolymer Powder, and Molded Article Using Ultra-High Molecular Weight Ethylene-Based Copolymer Powder - An ultra-high molecular weight ethylene-based copolymer powder comprising:
| 2019-01-03 |
20190002612 | ETHYLENE-VINYL ALCOHOL COPOLYMER COMPOSITION PELLETS, AND MULTILAYER STRUCTURE - An ethylene-vinyl alcohol copolymer composition is provided, which contains an ethylene-vinyl alcohol copolymer and an iron compound, wherein the ethylene-vinyl alcohol copolymer has an ethylene content of 20 to 60 mol %, wherein the iron compound is present in a proportion of 0.01 to 100 ppm on a metal basis based on the weight of the ethylene-vinyl alcohol copolymer composition. | 2019-01-03 |
20190002613 | HYDROPHOBICALLY MODIFIED ALKALI-SWELLABLE EMULSION POLYMERS - The present technology relates to hydrophobically modified alkali-swellable emulsion polymers that are useful as rheology modifiers. More specifically the present technology relates to hydrophobically modified alkali-swellable emulsion polymers containing residues of a polyunsaturated amphiphilic macromonomer. In one aspect the disclosed polymers are useful for thickening aqueous surfactant containing compositions, while providing the compositions in which they are included excellent rheology properties, clarity, and the ability to stably suspend insoluble and particulate materials over long periods of time. | 2019-01-03 |
20190002614 | METHOD FOR PREPARING CONCRETE SUPERPLASTICIZER HAVING PHOSPHOROUS ACID GROUP AND USE THEREOF - The present invention discloses a method for preparing a concrete superplasticizer having a phosphorous acid group and a use of the concrete superplasticizer. The concrete superplasticizer having a phosphorous acid group according to the present invention is prepared by free radical copolymerization of a phosphorous-containing monomer A and a polyether macromonomer B. The concrete superplasticizer having a phosphorous acid group obtained in the present invention can effectively improve flowability of concrete and can retain good workability of concrete. The method is simple, economical and effective, and in particular, can be used for commercial mass production. | 2019-01-03 |